查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606259

骨癌治療市場：按類型、治療方法、通路分類 - 全球預測 2025-2030

Bone Cancer Treatment Market by Type (Chondrosarcoma, Ewing's Sarcoma, Multiple Myeloma), Treatment (Chemotherapy, Radiation Therapy, Surgery), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年骨癌治療市場價值為47.8億美元，預計到2024年將達到52.4億美元，複合年成長率為15.06%，預計到2030年將達到127.7億美元。

骨癌治療市場範圍主要包括手術、化療、放射線治療等治療性介入以及標靶治療、免疫治療等新型治療方法。這些治療的需求是由於改善各種類型骨癌（包括骨癌、軟骨肉瘤和伊文氏肉瘤）患者的生存和生活品質的需求尚未得到滿足。範圍不僅延伸到透過醫院和癌症中心直接照護患者，也延伸到專注於提高治療效果的研究機構。最終用途領域包括醫療保健提供者、實驗室、生物製藥公司等。骨癌盛行率上升、醫療技術進步、醫療保健成本上升以及創新藥物配方等因素正在影響該市場的成長。電腦輔助藥物設計和精準醫學是快速成長的商機。基因研究和個人化醫療的投資可以開闢新的治療途徑。然而，挑戰包括高昂的治療成本、與傳統治療方法相關的副作用、監管障礙以及缺乏對新治療方法的認知，特別是在發展中地區。此外，與其他癌症類型相比，骨癌的盛行率較低，使其成為大型製藥公司研發投資的不有吸引力的目標，從而增加了該行業的局限性。在技​​術創新方面，次世代定序和人工智慧驅動的預測模型是探索早期診斷和客製化治療計劃的成熟領域。利用生物標記發現進行標靶治療有可能顯著改變治療模式。市場競爭仍然激烈，生技公司和學術研究人員之間的合作對於實現突破至關重要。鼓勵公司投資早期研究和臨床試驗的夥伴關係，並專注於微創和患者友好的選擇。了解監管途徑並主動與衛生當局互動可以幫助緩解特定市場的挑戰並加快產品開發週期。

主要市場統計
基準年[2023] 47.8億美元
預計年份 [2024] 52.4億美元
預測年份 [2030] 127.7億美元
複合年成長率（%） 15.06%

市場動態：快速發展的骨癌治療市場的關鍵市場洞察

供需的動態交互作用正在改變骨癌治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球骨癌盛行率上升
    • 傾向微創手術
    • 骨癌藥物和治療方法的核准增加
  • 市場限制因素
    • 治療費用上漲和藥品召回
  • 市場機會
    • 標靶治療和免疫治療取得重大進展
    • 骨癌研究的有利資助狀況
  • 市場挑戰
    • 與骨癌治療相關的副作用

波特五力：駕馭骨癌治療市場的策略工具

波特的五力框架是了解骨癌治療市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨癌治療市場的外部影響

外部宏觀環境因素在塑造骨癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解骨癌治療市場的競爭狀況

對骨癌治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣骨癌治療市場供應商績效評估

FPNV定位矩陣是評估骨癌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了骨癌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對骨癌治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球骨癌發生率正在上升
      • 微創手術趨勢
      • 骨癌藥物和治療方法的核准增加
    • 抑制因素
      • 治療費用上漲和藥品頻繁召回
    • 機會
      • 標靶治療和免疫治療的重大進展
      • 骨癌研究的有利資金籌措環境
    • 任務
      • 與骨癌治療相關的不良反應
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章骨癌治療市場：依類型

  • 軟骨肉瘤
  • 伊文氏肉瘤
  • 多發性骨髓瘤
  • 骨癌

第7章依治療分類的骨癌治療市場

  • 化療
  • 放射治療
  • 外科手術
  • 標靶治療

第8章骨癌治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章北美及南美骨癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區骨癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的骨癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aadi Biosciences
  • Advaxis, Inc.
  • Agios Pharmaceuticals
  • Amgen Inc.
  • Atlanthera
  • Baxter International Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cellectar Biosciences, Inc.
  • Eisai Limited
  • Eli Lilly and Company
  • Exelixis, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-B1685377A111

The Bone Cancer Treatment Market was valued at USD 4.78 billion in 2023, expected to reach USD 5.24 billion in 2024, and is projected to grow at a CAGR of 15.06%, to USD 12.77 billion by 2030.

The scope of the bone cancer treatment market primarily involves therapeutic interventions such as surgery, chemotherapy, radiation therapy, and novel treatments like targeted therapy and immunotherapy. The necessity for these treatments is driven by the unmet need to improve survival rates and the quality of life for patients suffering from different types of bone cancer, including osteosarcoma, chondrosarcoma, and Ewing sarcoma. The application scope covers not only direct patient care through hospitals and cancer centers but also extends to research institutions focusing on improving treatment efficacy. End-use sectors include healthcare providers, research laboratories, and biopharmaceutical companies. Influencing growth in this market are factors like the rising incidence of bone cancers, advancements in medical technology, increased healthcare spending, and innovative drug formulations. Computer-aided drug design and precision medicine are burgeoning opportunities. Investments in genetic research and personalized medicine could potentially unlock new therapeutic avenues. However, challenges include high treatment costs, side effects associated with conventional therapies, regulatory hurdles, and a lack of awareness about new treatment modalities, particularly in developing regions. The industry's limitations are further compounded by the low prevalence of bone cancer relative to other cancer types, making it less attractive for substantial R&D investment from large pharmaceutical companies. On the innovation front, next-generation sequencing and AI-powered predictive models are ripe areas for exploration, aimed at early diagnosis and customized treatment plans. Leveraging biomarker discoveries for targeted therapies could significantly alter treatment paradigms. The market remains competitive, with collaborations between biotech firms and academic researchers essential to drive breakthroughs. Companies are recommended to invest in partnerships aimed at early-stage research and clinical trials, focusing on minimally invasive and patient-friendly options. Understanding regulatory pathways and engaging in active dialogue with health authorities can mitigate some of the market's inherent challenges and accelerate product development cycles.

KEY MARKET STATISTICS
Base Year [2023] USD 4.78 billion
Estimated Year [2024] USD 5.24 billion
Forecast Year [2030] USD 12.77 billion
CAGR (%) 15.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bone Cancer Treatment Market

The Bone Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of bone cancer worldwide
    • Inclination towards minimally invasive surgical procedures
    • Increasing approval of drugs and therapies for bone cancer
  • Market Restraints
    • High cost of treatment and incidence of recall of drugs
  • Market Opportunities
    • Significant advancements in targeted therapy and immunotherapy
    • Favorable funding landscape for bone cancer research
  • Market Challenges
    • Adverse effects associated with bone cancer treatment

Porter's Five Forces: A Strategic Tool for Navigating the Bone Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bone Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bone Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bone Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bone Cancer Treatment Market

A detailed market share analysis in the Bone Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bone Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bone Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bone Cancer Treatment Market

A strategic analysis of the Bone Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bone Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Aadi Biosciences, Advaxis, Inc., Agios Pharmaceuticals, Amgen Inc., Atlanthera, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Cellectar Biosciences, Inc., Eisai Limited, Eli Lilly and Company, Exelixis, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk, Pfizer Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Bone Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chondrosarcoma, Ewing's Sarcoma, Multiple Myeloma, and Osteosarcoma.
  • Based on Treatment, market is studied across Chemotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of bone cancer worldwide
      • 5.1.1.2. Inclination towards minimally invasive surgical procedures
      • 5.1.1.3. Increasing approval of drugs and therapies for bone cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and incidence of recall of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant advancements in targeted therapy and immunotherapy
      • 5.1.3.2. Favorable funding landscape for bone cancer research
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with bone cancer treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bone Cancer Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Chondrosarcoma
  • 6.3. Ewing's Sarcoma
  • 6.4. Multiple Myeloma
  • 6.5. Osteosarcoma

7. Bone Cancer Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Radiation Therapy
  • 7.4. Surgery
  • 7.5. Targeted Therapy

8. Bone Cancer Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Bone Cancer Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bone Cancer Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bone Cancer Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aadi Biosciences
  • 2. Advaxis, Inc.
  • 3. Agios Pharmaceuticals
  • 4. Amgen Inc.
  • 5. Atlanthera
  • 6. Baxter International Inc.
  • 7. Bayer AG
  • 8. Bristol-Myers Squibb Company
  • 9. Cellectar Biosciences, Inc.
  • 10. Eisai Limited
  • 11. Eli Lilly and Company
  • 12. Exelixis, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Hikma Pharmaceuticals PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck and Co. Inc.
  • 17. Novartis AG
  • 18. Novo Nordisk
  • 19. Pfizer Inc.
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BONE CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BONE CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BONE CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BONE CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BONE CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BONE CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BONE CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BONE CANCER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY EWING'S SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BONE CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES BONE CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BONE CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BONE CANCER TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BONE CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM BONE CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. BONE CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. BONE CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023